InvestorsHub Logo
Followers 2
Posts 456
Boards Moderated 0
Alias Born 02/21/2012

Re: None

Wednesday, 09/25/2013 6:17:06 PM

Wednesday, September 25, 2013 6:17:06 PM

Post# of 429563
I wonder... If in a post Anchor approval world, will AMRN reps be able to pitch the value prop that using Vascepa allows patients to be on a reduced dose of statin, which obviously has bad side effects?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News